

Identification of therapeutic targets in patients with Squamous Cell Carcinoma of the Head and Neck who progress on or after anti-PD-(L)1 therapy - A IMMUCan sub-project

R/M SCCHN

Recurrent and/or metastatic Squamous Cell Carcinoma of the Head and Neck




Nivolumab and pembrolizumab : ORR 10-20%
-> only a minority of patients respond

No standard of care exists for patients who progress after platinum-based or anti-PD-1 therapy
-> median overall survival is dismal (5-6 months)


IMMUCan



A public-private EU-funded translational research study to generate broad molecular and cellular profiling data of tumors and their micro-environment

Will screen up to 3,000 patients with : 
Includes prospective cohorts and collaborates with **clinical trials**.

EORTC-HNCG-1559 Translational project



Funding

The IMMUCan project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821558. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. IMI.europa.eu.
More information about IMMUCan: www.immucan.eu

¹Institut de Recherche Clinique et Expérimentale (Pole MIRO),
Université Catholique de Louvain (UCLouvain), Brussels, Belgium
athenais.vanderelst@uclouvain.be

²Translational research, EORTC, Brussels, Belgium

³Merck KGaA, Darmstadt, Germany

⁴SIB, Lausanne, Switzerland

⁵on behalf of the IMMUCan consortium

⁶Institut Roi Albert II, Department of Medical Oncology,
Cliniques Universitaires Saint-Luc, Brussels, Belgium